Cargando…
Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study
OBJECTIVES: Preventing adverse events (AEs) after orthopaedic surgery is a field with great room for improvement. A Swedish instrument for measuring AEs after hip arthroplasty based on administrative data from the national patient register is used by both the Swedish Hip Arthroplasty Register and th...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429990/ https://www.ncbi.nlm.nih.gov/pubmed/30850403 http://dx.doi.org/10.1136/bmjopen-2018-023773 |
_version_ | 1783405704996978688 |
---|---|
author | Magnéli, Martin Unbeck, Maria Rogmark, Cecilia Rolfson, Ola Hommel, Ami Samuelsson, Bodil Schildmeijer, Kristina Sjöstrand, Desirée Gordon, Max Sköldenberg, Olof |
author_facet | Magnéli, Martin Unbeck, Maria Rogmark, Cecilia Rolfson, Ola Hommel, Ami Samuelsson, Bodil Schildmeijer, Kristina Sjöstrand, Desirée Gordon, Max Sköldenberg, Olof |
author_sort | Magnéli, Martin |
collection | PubMed |
description | OBJECTIVES: Preventing adverse events (AEs) after orthopaedic surgery is a field with great room for improvement. A Swedish instrument for measuring AEs after hip arthroplasty based on administrative data from the national patient register is used by both the Swedish Hip Arthroplasty Register and the Swedish Association of Local Authorities and Regions. It has never been validated and its accuracy is unknown. The aim of this study was to validate the instrument’s ability to detect AEs, and to calculate the incidence of AEs following primary hip arthroplasties. DESIGN: Retrospective cohort study using retrospective record review with Global Trigger Tool methodology in combination with register data. SETTING: 24 different hospitals in four major regions of Sweden. PARTICIPANTS: 2000 patients with either total or hemi-hip arthroplasty were recruited from the SHAR. We included both acute and elective patients. PRIMARY AND SECONDARY OUTCOME MEASURES: The sensitivity and specificity of the instrument. Adjusted cumulative incidence and incidence rate. RESULTS: The sensitivity for all identified AEs was 5.7% (95% CI: 4.9% to 6.7%) for 30 days and 14.8% (95% CI: 8.2 to 24.3) for 90 days, and the specificity was 95.2% (95% CI: 93.5% to 96.6%) for 30 days and 92.1% (95% CI: 89.9% to 93.8%) for 90 days. The adjusted cumulative incidence for all AEs was 28.4% (95% CI: 25.0% to 32.3%) for 30 days and 29.5% (95% CI: 26.0% to 33.8%) for 90 days. The incidence rate was 0.43 AEs per person-month (95% CI: 0.39 to 0.47). CONCLUSIONS: The AE incidence was high, and most AEs occurred within the first 30 days. The instrument sensitivity for AEs was very low for both 30 and 90 days, but the specificity was high for both 30 and 90 days. The studied instrument is insufficient for valid measurements of AEs after hip arthroplasty. |
format | Online Article Text |
id | pubmed-6429990 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-64299902019-04-05 Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study Magnéli, Martin Unbeck, Maria Rogmark, Cecilia Rolfson, Ola Hommel, Ami Samuelsson, Bodil Schildmeijer, Kristina Sjöstrand, Desirée Gordon, Max Sköldenberg, Olof BMJ Open Surgery OBJECTIVES: Preventing adverse events (AEs) after orthopaedic surgery is a field with great room for improvement. A Swedish instrument for measuring AEs after hip arthroplasty based on administrative data from the national patient register is used by both the Swedish Hip Arthroplasty Register and the Swedish Association of Local Authorities and Regions. It has never been validated and its accuracy is unknown. The aim of this study was to validate the instrument’s ability to detect AEs, and to calculate the incidence of AEs following primary hip arthroplasties. DESIGN: Retrospective cohort study using retrospective record review with Global Trigger Tool methodology in combination with register data. SETTING: 24 different hospitals in four major regions of Sweden. PARTICIPANTS: 2000 patients with either total or hemi-hip arthroplasty were recruited from the SHAR. We included both acute and elective patients. PRIMARY AND SECONDARY OUTCOME MEASURES: The sensitivity and specificity of the instrument. Adjusted cumulative incidence and incidence rate. RESULTS: The sensitivity for all identified AEs was 5.7% (95% CI: 4.9% to 6.7%) for 30 days and 14.8% (95% CI: 8.2 to 24.3) for 90 days, and the specificity was 95.2% (95% CI: 93.5% to 96.6%) for 30 days and 92.1% (95% CI: 89.9% to 93.8%) for 90 days. The adjusted cumulative incidence for all AEs was 28.4% (95% CI: 25.0% to 32.3%) for 30 days and 29.5% (95% CI: 26.0% to 33.8%) for 90 days. The incidence rate was 0.43 AEs per person-month (95% CI: 0.39 to 0.47). CONCLUSIONS: The AE incidence was high, and most AEs occurred within the first 30 days. The instrument sensitivity for AEs was very low for both 30 and 90 days, but the specificity was high for both 30 and 90 days. The studied instrument is insufficient for valid measurements of AEs after hip arthroplasty. BMJ Publishing Group 2019-03-07 /pmc/articles/PMC6429990/ /pubmed/30850403 http://dx.doi.org/10.1136/bmjopen-2018-023773 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/. |
spellingShingle | Surgery Magnéli, Martin Unbeck, Maria Rogmark, Cecilia Rolfson, Ola Hommel, Ami Samuelsson, Bodil Schildmeijer, Kristina Sjöstrand, Desirée Gordon, Max Sköldenberg, Olof Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study |
title | Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study |
title_full | Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study |
title_fullStr | Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study |
title_full_unstemmed | Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study |
title_short | Validation of adverse events after hip arthroplasty: a Swedish multi-centre cohort study |
title_sort | validation of adverse events after hip arthroplasty: a swedish multi-centre cohort study |
topic | Surgery |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429990/ https://www.ncbi.nlm.nih.gov/pubmed/30850403 http://dx.doi.org/10.1136/bmjopen-2018-023773 |
work_keys_str_mv | AT magnelimartin validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT unbeckmaria validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT rogmarkcecilia validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT rolfsonola validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT hommelami validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT samuelssonbodil validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT schildmeijerkristina validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT sjostranddesiree validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT gordonmax validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy AT skoldenbergolof validationofadverseeventsafterhiparthroplastyaswedishmulticentrecohortstudy |